Literature DB >> 18806208

Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccines.

Godfree Mlambo1, Nirbhay Kumar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18806208      PMCID： PMC2583535          DOI： 10.1128/EC.00242-08

Source DB:  PubMed          Journal:  Eukaryot Cell        ISSN： 1535-9786


× No keyword cloud information.
  37 in total

1.  Role of non-human primates in malaria vaccine development: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

2.  Evaluation of an in vitro assay aimed at measuring protective antibodies against sporozoites.

Authors:  S Mellouk; N Berbiguier; P Druilhe; M Sedegah; B Galey; L Yuan; M Leef; Y Charoenvit; C Paul; S Hoffman
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

3.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.

Authors:  Pedro L Alonso; Jahit Sacarlal; John J Aponte; Amanda Leach; Eusebio Macete; Jessica Milman; Inacio Mandomando; Bart Spiessens; Caterina Guinovart; Mateu Espasa; Quique Bassat; Pedro Aide; Opokua Ofori-Anyinam; Margarita M Navia; Sabine Corachan; Marc Ceuppens; Marie-Claude Dubois; Marie-Ange Demoitié; Filip Dubovsky; Clara Menéndez; Nadia Tornieporth; W Ripley Ballou; Ricardo Thompson; Joe Cohen
Journal:  Lancet       Date:  2004 Oct 16-22       Impact factor: 79.321

4.  Quantitative Plasmodium sporozoite neutralization assay (TSNA).

Authors:  Kota Arun Kumar; Giane A Oliveira; Robert Edelman; Elizabeth Nardin; Victor Nussenzweig
Journal:  J Immunol Methods       Date:  2004-09       Impact factor: 2.303

5.  Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children.

Authors:  Blaise Genton; Fadwa Al-Yaman; Inoni Betuela; Robin F Anders; Allan Saul; Kay Baea; Mata Mellombo; Jack Taraika; Graham V Brown; David Pye; David O Irving; Ingrid Felger; Hans-Peter Beck; Thomas A Smith; Michael P Alpers
Journal:  Vaccine       Date:  2003-12-08       Impact factor: 3.641

6.  Malaria transmission-blocking vaccines.

Authors:  D C Kaslow; I C Bathurst; P J Barr
Journal:  Trends Biotechnol       Date:  1992-11       Impact factor: 19.536

7.  Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa.

Authors:  Chandy C John; Rebecca A O'Donnell; Peter O Sumba; Ann M Moormann; Tania F de Koning-Ward; Christopher L King; James W Kazura; Brendan S Crabb
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

8.  Effector cells involved in nonspecific and antibody-dependent mechanisms directed against Plasmodium falciparum blood stages in vitro.

Authors:  F Lunel; P Druilhe
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

9.  Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals.

Authors:  P J Barr; K M Green; H L Gibson; I C Bathurst; I A Quakyi; D C Kaslow
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

10.  A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies.

Authors:  Tania F de Koning-Ward; Rebecca A O'Donnell; Damien R Drew; Russell Thomson; Terence P Speed; Brendan S Crabb
Journal:  J Exp Med       Date:  2003-09-08       Impact factor: 14.307
View more
  6 in total

1.  A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity.

Authors:  Anna L Goodman; Andrew M Blagborough; Sumi Biswas; Yimin Wu; Adrian V Hill; Robert E Sinden; Simon J Draper
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

2.  Enzymatic Characterization of Recombinant Food Vacuole Plasmepsin 4 from the Rodent Malaria Parasite Plasmodium berghei.

Authors:  Peng Liu; Arthur H Robbins; Melissa R Marzahn; Scott H McClung; Charles A Yowell; Stanley M Stevens; John B Dame; Ben M Dunn
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240

3.  Adeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming.

Authors:  Yenni Yusuf; Tatsuya Yoshii; Mitsuhiro Iyori; Kunitaka Yoshida; Hiroaki Mizukami; Shinya Fukumoto; Daisuke S Yamamoto; Asrar Alam; Talha Bin Emran; Fitri Amelia; Ashekul Islam; Hiromu Otsuka; Eizo Takashima; Takafumi Tsuboi; Shigeto Yoshida
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

4.  Optimization of flow cytometric detection and cell sorting of transgenic Plasmodium parasites using interchangeable optical filters.

Authors:  Ivan A Vorobjev; Kathrin Buchholz; Prashant Prabhat; Kenneth Ketman; Elizabeth S Egan; Matthias Marti; Manoj T Duraisingh; Natasha S Barteneva
Journal:  Malar J       Date:  2012-09-05       Impact factor: 2.979

5.  The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.

Authors:  Anna L Goodman; Emily K Forbes; Andrew R Williams; Alexander D Douglas; Simone C de Cassan; Karolis Bauza; Sumi Biswas; Matthew D J Dicks; David Llewellyn; Anne C Moore; Chris J Janse; Blandine M Franke-Fayard; Sarah C Gilbert; Adrian V S Hill; Richard J Pleass; Simon J Draper
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

6.  Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes.

Authors:  Timothy W Phares; Anthony D May; Christopher J Genito; Nathan A Hoyt; Farhat A Khan; Michael D Porter; Margot DeBot; Norman C Waters; Philippe Saudan; Sheetij Dutta
Journal:  Malar J       Date:  2017-03-13       Impact factor: 2.979
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.